| Literature DB >> 17991468 |
Vyacheslav Yurchenko1, Zhu Xue, Barbara Sherry, Michael Bukrinsky.
Abstract
A potent immunosuppressive drug cyclosporin A (CsA) is known to inhibit human cell infection by the pathogenic protozoan parasite Leishmania major both in vitro and in vivo. The proposed mechanism of action involves CsA binding to Leishmania major-expressed cyclophilin and subsequent down-regulation of signaling events necessary for establishing productive infection. Recently, we identified a ubiquitously expressed membrane protein, CD147, as a signaling receptor for extracellular cyclophilins in mammalian cells. Here we demonstrate that, while being enzymatically active, the Leishmania cyclophilin, unlike its human homologue, does not interact with CD147 on the cell surface of target cells. CD147 facilitates neither Leishmania binding nor infection. Primary structure and biochemical analyses revealed that the parasite's cyclophilin is defective in heparan binding, an event required for signaling interaction between CD147 and human cyclophilin. When the heparan-binding motif was reconstituted in Leishmania cyclophilin, it regained the CD147-dependent signaling activity. These results underscore a critical role of cyclophilin-heparan interactions in CD147-mediated signaling events and argue against the role of Leishmania cyclophilin in parasite binding to target cells.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17991468 PMCID: PMC2377454 DOI: 10.1016/j.ijpara.2007.10.001
Source DB: PubMed Journal: Int J Parasitol ISSN: 0020-7519 Impact factor: 3.981
Fig. 1CD147 does not facilitate Leishmania major infection or binding. (a) Half-confluent cultures of CHO.pcDNA (triangles) or CHO.CD147 (circles) cells were exposed to parasites for 6 h in serum-free medium at 33 °C. The level of infection was monitored at indicated times p.i. by light microscopy. Results (mean ± SD of three independent experiments) are presented as percentages of infected cells. The difference in infection rate between CHO.pcDNA and CHO.CD147 cell lines was not statistically significant. (b) CHO.CD147 cells were infected as in panel (a) in the presence of 1 μg/ml of CsA (squares) or 50 μg/ml of the blocking anti-CD147 antibody (circles) added together with the parasite. Nothing was added to control samples (triangles). Results are mean ± SD of three independent experiments. (c) Leishmania major promastigotes were radiolabeled and used to assess binding to indicated CHO cell lines. CHO.CD147+αCD147 denotes binding to cells pretreated with 50 μg/ml of anti-CD147 antibody; CHO.CD147+isotype are cells pretreated with 50 μg/ml of IgG1 isotype control antibody; CHO.pgsB-618.pcDNA are heparan-deficient cells transfected with pcDNA3.1; CHO.pgsB-618.CD147 are heparan-deficient cells transfected with CD147; and CHO.CD147+Heparitinase III denotes cells pretreated with Heparitinase III to remove heparans. Results are mean ± SD of three independent experiments.
Fig. 2LmCyp19 does not stimulate extracellular signal-regulated kinases (ERKs) phosphorylation. (a) Gel electrophoresis of recombinant cyclophilins expressed in Escherichia coli. (b) Purified cyclophilins (25 nM each) were used to stimulate CHO.CD147 and CHO.pcDNA cells. Control lanes show unstimulated cells. Total and phosphorylated ERKs (p42 and p44) were visualized by Western blotting with anti-p42/p44 (top) or anti-phospho-p42/p44 mAb (bottom), respectively. (c) Equal amounts of glutathione-S-transferase (GST), GST-CypA, GST-LmCyp19 or GST-LmCyp19 T164K, P168K were added to Heparin-agarose (5% of the added amount shown in upper panel), washed, eluted in Laemmli SDS sample buffer, separated by PAGE and visualized with anti-GST antibody (bottom panel).
Analysis of proline cis–trans isomerase activity of LmCyp19
| Cyclophilin | ||
|---|---|---|
| CypA | 0.07248 | 3.4854 × 106 |
| LmCyp19 | 0.05524 | 2.6158 × 106 |
| LmCyp19 T164K,P168K | 0.05397 | 2.4776 × 106 |
The Kcat/Km values were calculated after subtracting the background isomerization by fitting the data iteratively to a pseudo first-order kinetic equation (Rascher et al., 1998).
Fig. 3Sequence alignment of LmCyp19 and human CypA. Amino acids critical for cyclophilin enzymatic activity are shaded, residues responsible for heparan binding in CypA are in bold and underlined, mutated residues in LmCyp19 responsible for the loss of heparan-binding activity are in bold.